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(Received 5 March 1990) 
The first syntheses of fluorine-18 labeled inhibitors of GABA reuptake [(R,S)-I-{2-{4- 
[‘*F]fluoropheny1}pheny1}methoxyethyl]piperidine-3-carboxy1ic acid, (R,S)-I-{2-(4-[“F]fluorophenyl)(4- 
fluorophenyl)methoxyethyl}piperidine-3-carboxylic acid, and (R,S)-I-[2-((4~[‘*F]trifluoromethyl)phenyl} 
{ (4-trifluoromethyl)phenyl)-methoxyethyl]pi~ridine-3-carboxylic acid] are described. These N-substi- 
tuted nipecotic acid derivatives were prepared in no-carrier-added form by the condensation of the 
appropriately substituted [“Flbenzhydryl chlorides (prepared in three steps from [‘*F]fluoride ion) with 
N-(2-hydroxyethyl)nipecotic acid ethyl ester, followed by ester hydrolysis. Overall radiochemical 
yields were 17-28% (corrected, 150 min synthesis time). A simple new method for synthesis of a 
[‘sF]trifluoromethyl group by the nucleophilic substitution of a bromodifluoromethyl substituent has also 
been developed. 
Introduction 
Gamma aminobutyric acid (GABA) is an inhibitory 
amino acid neurotransmitter involved in the control 
of neuronal activity in the brain (Enna, 1980; 
Krogsgaard-Larsen et al., 1987). Dysfunctions of the 
GABA system have been implicated in a wide variety 
of neurological disorders, and are of particular inter- 
est in studies of epilepsy and other seizure disorders. 
In vivo approaches to. the study of the GABA system 
in man using positron emission tomography (PET) 
have centered on the preparation and application 
of radiolabeled ligands known to bind to the 
GABA/benzodiazepine receptor complex (Maziere et 
al., 1980, 1984; Frost et al., 1986). 
An alternative approach to the study of the role of 
degeneration of the GABA neurotransmitter path- 
way in disease would be development of in oivo 
markers of the presynaptic GABA-ergic neurons. 
Reasonable approaches are the development of radio- 
labeled synthetic precursors to GABA formation; 
radiolabeled inhibitors of the enzymes involved in 
GABA production (e.g. glutamic acid decarboxylase, 
GAD); or radiolabeled inhibitors of the presynaptic 
GABA reuptake system. This last option is particu- 
larly appealing due to the interest in developing drugs 
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that block this process for use in treatment of epilepsy 
(Krogsgaard-Larsen et al., 1987). The mechanisms 
of GABA uptake are not well understood, and there 
is relatively little data regarding in vivo pharmaco- 
kinetics and specificity of GABA uptake inhibitors. 
We describe here the first synthesis of novel 18F 
labeled GABA uptake inhibitors (Fig. 1: Pavia, 
1988; Taylor and Vartanian, 1989) as potential 
radioligands for studying the GABA system by 
in vivo methods (ex vivo tissue counting, in vivo 
autoradiography, and PET). 
Materials 
Experimental 
The following were obtained from Aldrich Chemi- 
cal Co. and used without further purification: tereph- 
thaldehyde, diethylaminosulfur trifluoride (DAST), 
4-bromobenzotrifluoride, Kryptofix 2.2.2, lithium 
aluminum hydride (1 M in diethyl ether). The quater- 
nary ammonium resin was prepared as previously 
described (Mulholland et al. 1989b). High specific 
activity (50,000 Ci/mmol) [‘8F]fluoride ion was 
produced by proton irradiation of [‘80]water held 
in an all silver cyclotron target as previously 
described (Mulholland et al., 1989a). Preparations of 
4-[“Flfluorobenzhydryl chloride (11) (Haka et al., 
1989) and 4-[“Flfluoro-4’-fluorobenzhydryl chloride 
(12) (Haka and Kilbourn, 1990) were according to 
literature methods. 
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3 X = CF,, Y = CF,18F 
Fig. I. Fluorine-18 labeled inhibitors of GABA reuptake. 
Methods 
Melting points were determined on a Thomas- 
Hoover capillary melting point apparatus and are 
uncorrected. NMR spectra were recorded with a 
Varian EM-390 spectrometer using TMS as internal 
reference. Infrared spectra were recorded with a 
Nicolet XS-20 FT-IR spectrometer using KBr plates. 
Thin layer chromatography was done using plastic- 
backed silica gel plates (Merck) and the following 
systems: System A, silica gel, 5/2 pentane/diethyl 
ether; System B, silica gel, 7/3 hexane/ethylacetate; 
System C, 7/2.5/0.5 toluene/isopropanol/acetic acid. 
HPLC was done using a Phenomenex Cl8 10~ 
0.45 x 10 cm column fitted with U.V. (263 nm) and 
radioactivity detectors, and a mobile phase of 60/40/3 
acetonitrile/0.065 M aqueous ammonium acetate/ 
tetrahydrofuran (flow rate 0.5 mL/min). 
All radiochemical yields are corrected for decay of 
‘“F (t,,* = I IO min). 
4-(D@oromethyl)benzaIdehyde (5). Terephthalde- 
hyde (4: 38 g, 0.28 mol) was dissolved in dichloro- 
methane (350mL), a nitrogen atmosphere intro- 
duced, and the mixture cooled to - 10°C. A solution 
of DAST (38 g, 0.24mol) in dichloromethane 
(50 mL) was added dropwise over 1 h. The reaction 
was stirred for 4 days at room temperature, quenched 
very carefully by slow (30 min) addition of water 
(25 mL), and neutralized with saturated aqueous 
NaHCO,. The aqueous layer was repeatedly 
extracted with CH,Cl,, and the extracts dried 
(MgSO,). filtered through silica and evaporated in 
L’acuo at temperature < lO“C. The remaining oil 
(36 g) was distilled (113-l 15 ‘C, 20 torr) to give 19.9 g 
(54% yield) of the desired aldehyde 5, which was 
used in the next step without further purification. 
‘H-NMR (CDCI,) S 9.8 (bs, IH, CHO), 7.65-7.35 
(dd, 4H. ArH), 6.68 (t, lH, J = 55.9 Hz, CHF& 
(R,S)-a-[4-(Difluoromethyl)phenyl]-4-(trifluoro- 
methyl)benzenemethanol 6. 4 Bromobenzotrifluoride 
(2.25 g, IO mmol) was added dropwise to a mixture of 
magnesium metal (0.24g, IOmmol) in diethyl ether 
(30 mL). The reaction was initiated (manual crushing 
of Mg, addition of iodine crystal) and the 4-bromo- 
benzotrifluoride added at a rate sufficient to maintain 
reflux. When the addition was complete, the reaction 
was refluxed for an additional 45 min and then cooled 
to 0 C. Approximately one-fifth of this Grignard 
reagent was then added to a solution of 5 (0.31 g, 
2 mmol) dissolved in cold ether (2 mL, O’C). The 
reaction was monitored by TLC (silica, 10% 
EtOAc/hexane) which indicated incomplete con- 
sumption of aldehyde 5. A small additional amount 
of Grignard reagent was added and the reaction then 
judged complete by TLC. The mixture was diluted 
with ether and washed with saturated NH,CI 
solution. The organic layer was dried (MgSO,), 
filtered, and evaporated in vacua. Purification by flash 
column chromatography (silica, 15% EtOAcjhexane) 
and crystallization from hexane afforded 0.48 g 
(80% yield) of the product 6; m.p. 81-82°C; ‘H-NMR 
(CDCI,) 6 7.65-7.45 (m, 8H, ArH), 6.65 (t, IH. 
J = 56.6 Hz, CHF,), 5.94 (s, lH, CHOH), 2.10 (bs, 
IH, OH); MS 302 (MC), 301 (M+-1); i.r. (cm-‘) 
3350, 1619, 1425, 1376; Anal. Calcd for C,,H,, F,O: 
C, 59.61; H, 3.69. Found; C, 59.82; H, 3.64. 
[4-(D~~uoron~eth~l)phen~~l]-[4-(triJluorometh~l)- 
phenyljmethanone 7 The benzhydro16 (0.6 g, 2 mmol) 
was dissolved in acetone (30 mL) and cooled to 0°C. 
Jones reagent (CrO, / H, SO, / Hz 0) was added drop- 
wise until an orange color persisted. The reaction was 
stirred an additional 5 min then quenched by addition 
of methanol. The product was poured into ether. 
the solid removed, and the organic layer evaporated 
in uacuo. The residue was again taken up in 
ether, decanted from solids, and evaporated. 
The white solid obtained was recrystallized from 
hexane to afford 0.44g (74%) of the ketone 7; m.p. 
l3l-131.5’C; ‘H-NMR (CDCI,) 6 7.92-7.65 (m, 8H, 
ArH), 6.74 (t, IH, J = 56 Hz, CHF,); MS 300 (M+ ), 
281 (M+-19); i.r. (cm-‘) 1653, 1615,1578. 151 I, 1409, 
1331; Anal. Calcd for C,,H,F,O: C, 60.01; H, 3.02. 
Found: C, 60.01; H, 2.98. 
[4-(Bromodifluoromethyl)phenyl]-[(4-trijuoro- 
methyl) phenylhethanone 8. The benzophenone 7 
(3.0 g. IO mmol) was suspended in Ccl, (40 mL) and 
to this added anhydrous K,CO, (6.9 g, 50 mmol) and 
then Br, (I .76 g, 11 mmol). The reaction mixture was 
placed under an atmosphere of N, and illuminated 
with a 275W sunlamp which raised the temperature to 
45°C. After 24 h additional Br, (I .76 g, IO mmol) was 
added and the reaction continued for a total of 60 h, 
at which time TLC (silica, 5% EtOAC/hexane) showed 
complete conversion. The reaction mixture was 
cooled, diluted with CH,Cl,, and then washed with 
saturated aqueous soldium silfite and sodium chlor- 
ide solutions. The organic layer was dried (MgSO,) 
and evaporated to give a solid which was dissolved 
in I : I ethyl acetate/hexane and passed through a 
short column of silica. The solvent was evaporated 
and the solid remaining recrystallized from hexane to 
yield 3.4g (95%) of the ketone 8; m.p. 78-79 C; 
‘H-NMR (CDCI,) 6 7.94-7.74 (m, 8H, ArH); 
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MS 299 (M+-80), 207 (M+-172); i.r. (cm-‘) 1667, 
1612, 1581, 1411, 1324. Anal. Calcd for C,,H,BrF,O: 
C, 47.52; H, 2.13. Found: C, 47.52; H, 2.08. 
[‘*F]bis(4-Trifiuoromethyl)benzophenone 9. No- 
carrier-added tetrabutylammonium [‘*F]fluoride was 
prepared by combining tetrabutylammonium hy- 
droxide (2 pmol) and aqueous [‘*F]fluoride and evap- 
orating the water (IOOC, N2). Traces of water were 
removed by azeotropic distillation with acetonitrile, 
and the residue dissolved in dimethylsulfoxide 
(200 p L). Bromobenzophenone 8 (2 mg) was added, 
and the solution heated at 150°C for 20 min. The 
mixture was cooled, diluted with water, and passed 
through a C- 18 Sep-Pak. The solid phase was washed 
with water (5 mL) then the product eluted with 
diethylether (2 mL). Yields ranged from 20-75% with 
an average of 50%. The product 9 was used in the 
next step without further purification. TLC System 
A) R, = 0.57. 
(R,S)-[‘*F&is-(4-Trifluoromethyl)benzhydrol 10. 
To a solution of ketone 9 (lOOpCi-5 mCi) in diethyl 
ether was added LAH (200 uL of 1M in THF) and 
the solution allowed to stand at 25°C for 5 min. 
Excess LAH was carefully quenched with water, 2 N 
H, SO, added, and the mixture passed through a C- 18 
Sep-Pak. The product was eluted with diethyl ether 
(2 mL) and then ether dried (Na*SO,) to yield a 
solution of the desired alcohol 10 (yields 85-95%). 
This was not further purified but used in the next step 
in the sequence. TLC (System A) R, = 0.2. 
(R,S)-[‘*F&is(4-TriJuoromethyl)benzhydryl chlor- 
ide (23). Chlorination of the alcohol 10 was done in 
dichloromethane solution (1-1.5 mL) using 100 p L 
of phosphorus trichloride at 100°C (closed vessel). 
TLC showed complete chlorination after 35 min. The 
solvent and excess PCl, were removed by a slow 
stream of nitrogen, and the residue used in the next 
step without purification. TLC (System A) R, = 0.55. 
(R,S)-Ethyl l-[2-{(4-[‘*F]trifuoromethyl)phenyl~ 
J(4_trifluoromethyl)phenyllmethoxyethyl]-piperidine- 
3-carboxylate 16. To the residue of chloride 13 
was added ethyl N-(2-hydroxyethyl)-piperidine-3- 
carboxylate (10 mg), and the mixture heated at 155°C 
for 25 min. The resultant brown oil was dissolved in 
methanol (100 FL), diluted with water (2 mL) and 
extracted with diethyl ether. The ether layers were 
combined and dried (Na,SO,) and the ether 
evaporated (N, flow). The residue was dissolved in 
dichloromethane and passed through a short column 
of silica gel to yield the desired crude product 16. 
Yield 33%; TLC (System B) Rf = 0.43. 
(R,S)-Ethyl 1-[2-J(4-[‘8F]fluorophenyl)phenyl)meth- 
ox)lethyl]-piperidine-3-carboxylate (14). This conden- 
sation was performed as per synthesis of 16, using the 
chloride 11; yield 49%; TLC (System B) R,= 0.375. 
(R,S)-Ethyl-l-[2-(4-[‘nF]fluorophenyl)(4-Jluoro- 
phenyl)methoxyethyl]piperidine-3-carboxylate (15). 
This ester was prepared utilizing chloride 12 as per 
the synthesis of 14: yield 31%. TLC (System B) 
R, = 0.28; (System C)R, = 0.68. 
(R,S)-l-[2-{(4-[‘8F]Tripuoromethyl)phenylj {(4-tri- 
jIuoromethyl)phenyl~methoxyethyl]-piperidine-3- 
carboxylic acid (3). The crude ethyl ester 16 was 
dissolved in 3 drops 6 N H,S04 and heated (100°C) 
for 30 min. The acid solution was diluted with 6 mL of 
20 mM K,HPO, buffer (pH 6.5) and extracted with 
two 2 mL portions of 4/l chloroform/isopropanol. 
The organic layers were combined, dried, and evapor- 
ated in vacua. Yield 83%, radiochemical purity 95%; 
TLC (System C) R, = 0.42; HPLC R, = 8.88 min. 
(R,S)-I-[2-((4-[‘8F]Fluorophenyl)phenyl}methoxy- 
ethyl]-piperidine-3-carboxylic acid (1). Hydrolysis 
of the ethyl ester 14 was done as per the synthesis 
of 3. Yield 90%, radiochemical purity 97%; TLC 
(System B) Rf = 0.05, (System C) RI= 0.35; HPLC 
R, = 6.83 min. 
(R,S)-l-{2-(4-[‘8F]Fluorophenyl)(4-fluorophenyl)- 
methoxyethyljpiperidine-3-carboxylic acid (2). Hy- 
drolysis of the ester 15 was done as per synthesis 
of 3. Yield 85%, radiochemical purity 96%; TLC 
(System B) Rf = 0.05: (System C) Rf = 0.40; HPLC 
R, = 7.12 min. 
Results and Discussion 
Preparation of radiolabeled inhibitors of the high 
affinity GABA uptake system would form a new and 
potentially powerful method for examining the distri- 
bution and function of this neurotransmitter system 
in vivo. GABA uptake sites show a heterogeneous 
distribution in primate brain, with a more than 4-fold 
difference between areas of low concentration (pons, 
deep cerebellar nuclei) and those of high concen- 
tration (amygdala, hypothalamus, globus pallidus) 
(Enna, 1981). Similarly, regional variations in 
[3H]nipecotic acid binding to GABA uptake sites in 
human brain tissue samples has been reported 
(Simpson et al., 1988). 
Guvacine (1,2,5,6-tetrahydronicotinic acid) and 
nipecotic acid (3-piperidine-carboxylic acid) are 
potent in vitro inhibitors of GABA uptake into both 
neurons and ghal cells, with no affinity for GABA 
receptors (Krogsgaard-Larsen et al., 1987). These 
amino acids, however, do not readily pass the 
blood-brain barrier (BBB) and thus are not good 
candidates for radiolabeling with “C or “F 
([“CIGABA has been recently prepared (Antoni 
and Langstrom, 1989) but suffers the same in vivo 
limitation). Preparation of esters of such acids pro- 
vides prodrugs which do pass through the BBB and 
are hydrolyzed in the brain to the active parent drugs 
(Frey et al., 1979; Falch et al., 1978). Application of 
prodrugs to PET imaging, although interesting, may 
be too complicated for successful analysis of in vivo 
pharmacokinetics. The placement of small alkyl 
groups on the nitrogen in guvacine or nipecotic acid 
has resulted in compounds which are less active than 
the parent amino acids, but surprisingly the attach- 
ment of large lipophilic groups, such as diarylbutenyl 
(Ah et al., 1985; Braestrup et al., 1990; Sonnewald, 
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1987) or diarylmethoxyethyl groups, (Pavia, 1988; 
Falch and Krogsgaard-Larsen, 1989), provides com- 
pounds which are actually more active as GABA 
inhibitors (IC,, values of 67-30 nM) than the parent 
amino acids, and do show potent in vivo activity after 
systemic administration. One such compound, NO 
328 ((R)-N-[4,4-bis(3-methyl-2-thienyl)but-3-en-l- 
yllnipecotic acid), has been recently prepared in triti- 
ated form and its in vitro and in vivo behavior 
examined in some detail (Braestrup et al., 1990). 
Their results (Kn = 18 nM, and regional variation 
in binding to brain synaptosomes) are encouraging 
for further development of radiohgands for GABA 
uptake sites. As we have recently developed general 
routes to ‘*F labeled diarylmethanols (4-[‘*F]fluoro- 
benzhydrol, Haka et al., 1989; 4-([‘*F]fluorophenyl) 
(2-thienyl)methanol, Kilbourn, 1989; 4-[“Flfluoro-4’- 
fluorobenzhydrol, Haka and Kilbourn, 1990), the 
application of such precursors to synthesis of ‘“F 
labeled derivatives of these cyclic amino acids 
appeared promising. A large number of substituted 
diphenylmethoxyethyl derivatives of nipecotic acid 
and guvacine have been recently reported (Pavia, 
1988) and we chose to prepare fluoroaryl (1,2) and 
trifluoromethyl (3) substituted diarylmethoxyethyl 
derivatives to test the feasibility of our synthetic 
approach. The reported IC,, for GABA uptake for 
compound 3 (as the R(-) stereoisomer) is 200 nM 
(Taylor and Vartanian, 1989); data for the other two 
compounds have not been reported. The K, values, 
which for NO 328 (18 nM) is significantly lower than 
the IC,, for GABA uptake (67 nM), have also not yet 
been reported. 
Synthesis of the target molecules was broken 
down into two parts, the preparation of the appro- 
priately labeled benzhydryl chlorides (11,12,13), 
followed by condensation with the ethyl ester 
of N-(2-hydroxyethyl)nipecotic acid. High specific 
activity 4-[‘8F]fluorobenzhydryl chloride (11) and 
4-[ 18F]fluoro-4’-fluorobenzhydryl chloride (12) were 
prepared by minor modifications of previously 
described methods. The j8F labeled bis(trifluoro- 
methyl)benzhydryl chloride (13) was prepared by the 
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Fig. 2. Synthesis of [ ‘RF]bis(4-trifluoromethyl)benzhydryl chloride 
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fluorinated (DAST; 54% yield) and the intermediate 
4-difluoromethylbenzaldehyde (5) reacted with 4-tri- 
fluoromethylphenylmagnesium bromide to give the 
benzhydrol 6 in 80% yield. The alcohol was oxidized 
to the ketone (7, 74% yield) using Jones reagent 
under standard conditions. Bromination of the 
difluoromethyl group was performed using bromine 
in Ccl, under photolytic conditions (90% yield), with 
solid potassium carbonate added to consume HBr 
formed in the reaction. This bromodifluoromethyl 
group was then converted to a “F labeled 
trifluoromethyl group by a simple reaction with 
no-carrier-added [“Fjfluoride ion (as salt with tetra- 
butylammonium, K+/Kryptofix, or quaternary am- 
monium resin (Mulholland et al., 1989b) counterion) 
in 50% yield (average; 25 min reaction time). The 
ease of this synthesis of a [“Fltrifluoromethyl group 
was surprising since previous attempts at r8F-for-“F 
(Ido et al., 1987) or “F-for-Cl (Angelini et al., 1986) 
substitutions required high temperature and/or Lewis 
acid catalysts, and products were obtained in only 
moderate yields. The ketone 9 was then reduced (10: 
LAH; 90% yield) and chlorinated (PCI, in CH,CI, or 
neat SOCI,; 955100% yield) to give the required 
benzylic chloride 13. 
11 X = H, Y =“F 
12 X = F, Y =“F 
13 X = CF3, Y = CF; ‘F 4 
The benzhydryl chlorides 11,12,13 were reacted 
with (N-2-hydroxyethyl)nipecotic acid ethyl ester 
(Fig. 3) to yield the intermediate ethers 14,15,16 in 
3349% yields. The products were separated from 
unreacted benzylic chlorides by extraction of the 
piperidine derivatives into dilute aqueous acid, and 
from excess N-hydroxynipecotic acid ester by a short 
column of silica gel. Finally, the ester groups were 
hydrolyzed under acidic conditions to yield the free 
amino acids 1,2,3. Products were obtained in high 
radiochemical purities (> 95% by TLC and/or 
HPLC) but all contained trace amounts of chemical 
impurities. Small amounts of chemically pure 
products were obtained after injection of portions of 
the crude products on the analytical HPLC column. 
All of the final product acids 1,2 and 3 have been 
obtained as racemic mixtures (mixtures of isomers at 
the carboxylic acid position) and compound 1 as also 
a mixture of isomers at the benzylic position. 
In this work we have demonstrated the feasibility of 
preparing 0. l-l .O mCi amounts of “F labeled deriva- 
tives of compounds known to be systemically active 
as GABA uptake inhibitors. Overall radiochemical 
yields (5 steps from resolubilized [“Flfluoride ion) 




15 X = F, Y =’ ‘F 
HCI 
COOH 
2 X = F, Y =’ ‘F 
Fig. 3. Synthesis of 18F labeled GABA uptake inhibitors. 
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time). The mono- and bisfluoro derivatives 1 and 2 
have been obtained in high specific activity 
( > 2000 Ci/mmol). The bis(trifluoromethy1) substi- 
tuted derivative, 3, has also been obtained in no- 
carrier-added form, but it requires a separation from 
small amounts of the compound bearing the original 
bromodifluoromethyl group; without this separation, 
the effective specific activity should be more properly 
described as lower (about 1 Ci/mmol) as the chemical 
contaminant is likely to be biologically active. These 
specific activities have been sufficient to begin in viuo 
testing of the compounds in small animals. The effect 
of stereochemistry at the benzylic position in 1 is 
unknown, but the R( - ) isomer of nipecotic acid and 
its derivatives are more potent inhibitors of GABA 
uptake (Pavia, 1988; Taylor and Vartanian, 1989). 
Syntheses of the R( -) isomers (carboxylic acid 
position) should provide better radiotracers, and are 
currently underway in our laboratories, as is the 
preparation of the corresponding guvacine deriva- 
tives(e.g. I-{2-{bis(trifluoromethyl)phenyl}methoxy}- 
ethyl)-1,2,5,6-tetrahydro-3-pyridine carboxylic acid, 
(X-966: (Pavia, 1988; Brahce et al., 1989) and thienyl- 
substituted derivatives (Kilbourn, 1989). Preliminary 
in riuo studies of regional mouse brain distribution of 
1 have been encouraging, with a cortex/striatum ratio 
(% injected dose per gram) of 1.44 + 0.36 at 1 h after 
injection; this compares favorably with the ratio of 
1.53 for spec$c binding of [‘HINO 328 to rat brain 
synaptosomes determined in aitro (Braestrup et al., 
1990). The availability of radiolabeled hgands will 
allow examination of in cit’o characteristics of this 
class of compounds (brain extraction; regional distri- 
bution and specificity of radiotracer binding in brain; 
kinetics of radiotracer accumulation and washout 
from brain; pharmacological specificity of binding; 
neuronal vs glial specificity). 
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